"Limits to Copying Boston... K-Bio Needs to Link Existing Hubs"
Report by the Biohealth Policy Research Center of the Korea Health Industry Development Institute
Weak Growth Pathway Connecting Startup, Clinical Trials, Investment, and Exit
"Need for Hospitals to Serve as R&D Platforms and for Policy Coor
It has been analyzed that for Korea’s bioindustry to strengthen its global competitiveness, universities, hospitals, companies, and capital, which are currently scattered across the country, must be connected into a single ecosystem. Although major bio hubs such as Songdo and Osong have already been established, there are concerns that the growth pathway from startup, research and development (R&D), clinical trials, investment, and exit remains weak.
On July 7, the Biohealth Policy Research Center of the Korea Health Industry Development Institute published a report titled "Startup and Cluster Model Study through Analysis of the Boston Bio Ecosystem." The report analyzes the factors behind the success of the Boston-Cambridge ecosystem in the United States, which is considered the world’s leading bio cluster, and presents policy challenges that can be applied to the Korean bioindustry.
Excerpt from the report 'Research on Startup and Cluster Models through Analysis of the Boston Bio-Ecosystem'. Korea Health Industry Development Institute
View original imageAccording to the report, Boston’s status as the world’s top bio cluster is rooted in high research density and long-term policy support. Massachusetts, where Boston is located, employs 117,108 people in the biopharmaceutical sector, with a related gross domestic product (GDP) of 42 billion dollars and 2,071 drug candidates in the pipeline. Although the state accounts for only 2% of the U.S. population, as of 2024 it secured 3.46 billion dollars in National Institutes of Health (NIH) research funding, which corresponds to 9.3% of the total NIH research grant budget. Massachusetts General Hospital (MGH) alone received 655 million dollars in NIH research funding.
The report identifies five core operational principles driving Boston’s success: the “density” of universities, hospitals, companies, and venture capital (VC) all located within walking distance; public risk-sharing by the state government; hospitals serving as R&D platforms; talent circulation across professors, entrepreneurs, investors, and management; and policy continuity regardless of political party changes.
The report concludes that the key is not to simply replicate Boston’s facilities or systems, but to adapt these operational principles to the Korean context. Korea possesses world-class hospitals, capabilities in biosimilars and contract development and manufacturing organizations (CDMOs), nationwide health insurance data, government R&D budgets, and multiple bio clusters. However, these assets remain divided by region and government ministry, meaning they are not fully connected as a single industrial ecosystem.
As short-term tasks, the report suggests networking startup infrastructures such as the Songdo K-Bio Lab Hub, the Pangyo Open Innovation Base, and the Nowon Seoul Digital Bio City (S-DBC). The intent is not to simply provide occupancy space, but to design pathways that extend to R&D funding, clinical networks, investment matching, and collaborations with global pharmaceutical companies.
Strengthening the role of hospitals was also highlighted as a major task. In Boston, large hospitals function not only as medical institutions but also as hubs for basic research, technology transfer, and spin-off startups. In contrast, despite the excellent clinical capabilities of Korean research-centered hospitals, their ability to commercialize technologies is limited due to constraints on reinvestment of research revenues and a shortage of physician-scientists. The report recommends reflecting hospitals’ achievements in technology transfer, spin-offs, and joint research in evaluation criteria, and calls for institutional reforms to encourage concurrent posts and entrepreneurship by physician-scientists.
For the mid-term, the report proposes establishing an operational system to coordinate bio clusters nationwide. This is because bio policies are dispersed across multiple ministries, including the Ministry of Health and Welfare, the Ministry of Trade, Industry and Energy, the Ministry of Science and ICT, the Ministry of SMEs and Startups, and the Ministry of Food and Drug Safety, which can result in overlapping investments and confusion over roles. However, the report argues that rather than assuming the need to create a new institution, it is better to first consider using existing bodies such as the National Bio Innovation Committee, separating policy coordination and field execution functions.
In the long term, the report stresses the importance of creating a self-sustaining, privately-driven virtuous cycle. In Boston, investment returns through mergers and acquisitions (M&A), reinvestment by successful entrepreneurs, and research reinvestment from university and hospital technology transfer incomes are all interconnected, fueling new startups. The report explains that Korea should also promote bio M&As and secondary markets to establish a system where capital and talent flow back into early-stage companies.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Park Soonman, Senior Researcher at the Biohealth Policy Research Center of the Korea Health Industry Development Institute, stated, "While Boston’s 50-year history and the research density of Kendall Square are unique assets that cannot be replicated overnight, the five core operational principles can be universally applied. Korea’s bio clusters must grow not as mere copies but as global innovation hubs with unique competitive strengths."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.